PIN1 and acute promyelocytic leukemia: ATRA inhibits PIN1 and leads to its degradation, thereby destabilising PML‐RARα (aberrant promyelocytic leukaemia‐retinoic acid receptor α), to which PIN1 binds, and contrasting the proliferation of acute promyelocytic leukaemia cells.